Review ArticleInterleukin-6: a villain in the drama of pancreatic cancer development and progression
References (97)
- et al.
European cancer mortality predictions for the year 2013
Ann Oncol
(2013) - et al.
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
Eur J Cancer
(2013) - et al.
Inflammatory networks and immune surveillance of pancreatic carcinoma
Curr Opin Immunol
(2013) - et al.
Inflammatory cytokines in human pancreatic cancer
Cancer Lett
(2014) - et al.
Interleukin-6 in inflammatory and malignant diseases of the pancreas
Semin Immunol
(2014) - et al.
Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma
Eur J Cell Biol
(2011) - et al.
Local recurrence of pancreatic cancer after primary surgical intervention: how to deal with this devastating scenario?
Surg Oncol
(2011) - et al.
Chronic pancreatitis: a path to pancreatic cancer
Cancer Lett
(2014) - et al.
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice
Cancer Cell
(2007) - et al.
EMT and dissemination precede pancreatic tumor formation
Cell
(2012)
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study
Gastrointest Endosc
(2012)
Interleukin-6 signaling pathway in targeted therapy for cancer
Cancer Treat Rev
(2012)
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Pharmacol Ther
(2014)
Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Semin Immunol
(2014)
Stat3 as an oncogene
Cell
(1999)
The two faces of IL-6 in the tumor microenvironment
Semin Immunol
(2014)
Interleukin-6 in bone metastasis and cancer progression
Eur J Cancer
(2010)
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer
Cancer Cell
(2011)
Cachexia in pancreatic cancer: new treatment options and measures of success
HPB (Oxford)
(2010)
Cancer cachexia: mediators, signaling, and metabolic pathways
Cell Metab
(2012)
Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression
Cancer Cell
(2011)
Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages
Eur J Cancer
(2004)
Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis
Immunobiology
(2012)
Cancer facts & figures – 2013, 2013 [cited 2014 Apr 10] 2013 Jan 2
Pancreatic cancer
Annu Rev Pathol
(2008)
Pancreatic cancer
N Engl J Med
(2010)
Smarter drugs emerging in pancreatic cancer therapy
Ann Oncol
(2014 Mar 14)
Stromal biology and therapy in pancreatic cancer
Gut
(2011)
The pancreas cancer microenvironment
Clin Cancer Res
(2012)
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer
Cancer Res
(2007)
The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion
Front Physiol
(2012)
Exploiting inflammation for therapeutic gain in pancreatic cancer
Br J Cancer
(2013)
Kras as a key oncogene and therapeutic target in pancreatic cancer
Front Physiol
(2014)
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma
Front Physiol
(2014)
Superiority of extended neoadjuvant chemotherapy with gemcitabine in pancreatic cancer: a comparative analysis in a clinically adapted orthotopic xenotransplantation model in SCID beige mice
Cancer Biol Ther
(2007)
Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies
World J Gastroenterol
(2014)
Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group
N Engl J Med
(1993)
Discovering the route from inflammation to pancreatic cancer
Minerva Gastroenterol Dietol
(2012)
Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras
Cancer Cell
(2009)
Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor
Cancer Res
(2007)
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
Invest New Drugs
(2005)
NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review)
Int J Oncol
(2006)
Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis
Cancer Res
(2008)
Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease
Pancreas
(2013)
Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer
Proc Natl Acad Sci U S A
(1997)
Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer
Cancer Sci
(2008)
CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer
Int J Cancer
(2009)
IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6
Int J Biol Sci
(2012)
Cited by (87)
Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors
2024, International Review of Cell and Molecular BiologyStrategies for drug targeting in pancreatic cancer
2022, PancreatologyJAK2/STAT3 pathway regulates microglia polarization involved in hippocampal inflammatory damage due to acute paraquat exposure
2022, Ecotoxicology and Environmental Safety
Published online May 14, 2014.
Copyright © 2014 The Editorial Board of Hepatobiliary & Pancreatic Diseases International. Published by Elsevier (Singapore) Pte Ltd. All rights reserved.